Table 1.
Patient characteristics in the test and training cohorts
| Test cohort | Training cohort | |||||
|---|---|---|---|---|---|---|
| PD-L1+ (n=41), n (%) | PD-L1− (n=41), n (%) | Overall (n=82), n (%) | PD-L1+ (n=28), n (%) | PD-L1− (n=20), n (%) | Overall (n=48), n (%) | |
| Age (year) | ||||||
| Average | 70 | 73 | 72 | 70 | 68 | 69 |
| Range | 38-93 | 57-86 | 38-93 | 50-87 | 36-84 | 36-87 |
| Sex | ||||||
| Male | 26 (63) | 17 (41) | 43 (52) | 12 (43) | 13 (65) | 25 (52) |
| Female | 15 (37) | 24 (59) | 39 (48) | 16 (57) | 7 (35) | 23 (48) |
| Smoking history | ||||||
| Current/former smoker | 31 (76) | 30 (73) | 61 (74) | 21 (75) | 13 (65) | 34 (71) |
| Never smoker | 4 (10) | 7 (17) | 11 (13) | 3 (11) | 3 (15) | 6 (13) |
| N/A | 6 (15) | 4 (10) | 10 (12) | 4 (14) | 4 (20) | 8 (17) |
| Overall stages | ||||||
| IA/IB | 11 (27) | 16 (39) | 27 (33) | 7 (25) | 8 (40) | 15 (31) |
| IIA/IIB | 6 (15) | 11 (27) | 17 (21) | 5 (18) | 2 (10) | 7 (15) |
| IIIA/IIIB | 10 (24) | 7 (17) | 17 (21) | 3 (11) | 2 (10) | 5 (10) |
| IV | 8 (20) | 6 (15) | 14 (17) | 11 (39) | 8 (40) | 19 (40) |
| N/A | 6 (15) | 1 (2) | 7 (8) | 2 (7) | 0 | 2 (4) |
| Histology subtypes | ||||||
| Adenocarcinoma | 30 (73) | 31 (76) | 61 (74) | 20 (71) | 17 (85) | 37 (77) |
| SCC | 7 (17) | 10 (24) | 17 (21) | 7 (25) | 3 (15) | 10 (21) |
| Adenosquamous | 4 (10) | 0 | 4 (5) | 1 (4) | 0 | 1 (2) |
Tumor PD-L1 + and PD-L1−status were determined using immunohistochemistry staining. N/A=Information not available, SCC=Squamous cell carcinoma, PD-L1=Programmed death-ligand 1, PD-L1+=PD-L1 positive, PD-L1−=PD-L1 negative